Santtu Heinonen1, Tuomas Jartti2, Carla Garcia3, Silvia Oliva4, Cynthia Smitherman5, Esperanza Anguiano5, Wouter A A de Steenhuijsen Piters6, Tytti Vuorinen7, Olli Ruuskanen2, Blerta Dimo1, Nicolas M Suarez1, Virginia Pascual5, Octavio Ramilo1,8,9, Asuncion Mejias1,8,9. 1. 1 Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, and. 2. 2 Department of Pediatrics and. 3. 3 Division of Pediatric Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, Texas. 4. 4 Division of Pediatric Emergency Medicine and Critical Care, Regional University Hospital of Malaga, Malaga, Spain. 5. 5 Baylor Institute for Immunology Research, Dallas, Texas. 6. 6 Department of Pediatric Immunology and Infectious Diseases, The Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, the Netherlands; and. 7. 7 Department of Clinical Virology, Turku University Hospital, Turku, Finland. 8. 8 Division of Pediatric Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio. 9. 9 The Ohio State University College of Medicine, Columbus, Ohio.
Abstract
RATIONALE: Rhinoviruses (RVs) are a major cause of symptomatic respiratory tract infection in all age groups. However, RVs can frequently be detected in asymptomatic individuals. OBJECTIVES: To evaluate the ability of host transcriptional profiling to differentiate between symptomatic RV infection and incidental detection in children. METHODS: Previously healthy children younger than 2 years old (n = 151) were enrolled at four study sites and classified into four clinical groups: RV- healthy control subjects (n = 37), RV+ asymptomatic subjects (n = 14), RV+ outpatients (n = 30), and RV+ inpatients (n = 70). Host responses were analyzed using whole-blood RNA transcriptional profiles. MEASUREMENTS AND MAIN RESULTS: RV infection induced a robust transcriptional signature, which was validated in three independent cohorts and by quantitative real-time polymerase chain reaction with high prediction accuracy. The immune profile of symptomatic RV infection was characterized by overexpression of innate immunity and underexpression of adaptive immunity genes, whereas negligible changes were observed in asymptomatic RV+ subjects. Unsupervised hierarchical clustering identified two main clusters of subjects. The first included 93% of healthy control subjects and 100% of asymptomatic RV+ subjects, and the second comprised 98% of RV+ inpatients and 88% of RV+ outpatients. Genomic scores of healthy control subjects and asymptomatic RV+ children were similar and significantly lower than those of RV+ inpatients and outpatients (P < 0.0001). CONCLUSIONS: Symptomatic RV infection induced a robust and reproducible transcriptional signature, whereas identification of RV in asymptomatic children was not associated with significant systemic transcriptional immune responses. Transcriptional profiling represents a useful tool to discriminate between active infection and incidental virus detection.
RATIONALE: Rhinoviruses (RVs) are a major cause of symptomatic respiratory tract infection in all age groups. However, RVs can frequently be detected in asymptomatic individuals. OBJECTIVES: To evaluate the ability of host transcriptional profiling to differentiate between symptomatic RV infection and incidental detection in children. METHODS: Previously healthy children younger than 2 years old (n = 151) were enrolled at four study sites and classified into four clinical groups: RV- healthy control subjects (n = 37), RV+ asymptomatic subjects (n = 14), RV+ outpatients (n = 30), and RV+ inpatients (n = 70). Host responses were analyzed using whole-blood RNA transcriptional profiles. MEASUREMENTS AND MAIN RESULTS:RV infection induced a robust transcriptional signature, which was validated in three independent cohorts and by quantitative real-time polymerase chain reaction with high prediction accuracy. The immune profile of symptomatic RV infection was characterized by overexpression of innate immunity and underexpression of adaptive immunity genes, whereas negligible changes were observed in asymptomatic RV+ subjects. Unsupervised hierarchical clustering identified two main clusters of subjects. The first included 93% of healthy control subjects and 100% of asymptomatic RV+ subjects, and the second comprised 98% of RV+ inpatients and 88% of RV+ outpatients. Genomic scores of healthy control subjects and asymptomatic RV+ children were similar and significantly lower than those of RV+ inpatients and outpatients (P < 0.0001). CONCLUSIONS: Symptomatic RV infection induced a robust and reproducible transcriptional signature, whereas identification of RV in asymptomatic children was not associated with significant systemic transcriptional immune responses. Transcriptional profiling represents a useful tool to discriminate between active infection and incidental virus detection.
Authors: G P Rakes; E Arruda; J M Ingram; G E Hoover; J C Zambrano; F G Hayden; T A Platts-Mills; P W Heymann Journal: Am J Respir Crit Care Med Date: 1999-03 Impact factor: 21.405
Authors: Wai-Ming Lee; Robert F Lemanske; Michael D Evans; Fue Vang; Tressa Pappas; Ronald Gangnon; Daniel J Jackson; James E Gern Journal: Am J Respir Crit Care Med Date: 2012-08-23 Impact factor: 21.405
Authors: Yijie Zhai; Luis M Franco; Robert L Atmar; John M Quarles; Nancy Arden; Kristine L Bucasas; Janet M Wells; Diane Niño; Xueqing Wang; Gladys E Zapata; Chad A Shaw; John W Belmont; Robert B Couch Journal: PLoS Pathog Date: 2015-06-12 Impact factor: 6.823
Authors: Nicolas M Suarez; Eleonora Bunsow; Ann R Falsey; Edward E Walsh; Asuncion Mejias; Octavio Ramilo Journal: J Infect Dis Date: 2015-01-29 Impact factor: 5.226
Authors: Tuomas Jartti; Kohei Hasegawa; Jonathan M Mansbach; Pedro A Piedra; Carlos A Camargo Journal: J Allergy Clin Immunol Date: 2015-03-31 Impact factor: 10.793
Authors: Aino Ruohola; Melinda M Pettigrew; Laura Lindholm; Jari Jalava; Kati S Räisänen; Raija Vainionpää; Matti Waris; Paula A Tähtinen; Miia K Laine; Elina Lahti; Olli Ruuskanen; Pentti Huovinen Journal: J Infect Date: 2012-12-22 Impact factor: 6.072
Authors: Tuomas Jartti; Maria Söderlund-Venermo; Klaus Hedman; Olli Ruuskanen; Mika J Mäkelä Journal: Paediatr Respir Rev Date: 2012-05-05 Impact factor: 2.726
Authors: Inesz van Benten; Laurens Koopman; Bert Niesters; Wim Hop; Barbara van Middelkoop; Leon de Waal; Kees van Drunen; Albert Osterhaus; Herman Neijens; Wytske Fokkens Journal: Pediatr Allergy Immunol Date: 2003-10 Impact factor: 6.377
Authors: Charles Langelier; Matt S Zinter; Katrina Kalantar; Gregory A Yanik; Stephanie Christenson; Brian O'Donovan; Corin White; Michael Wilson; Anil Sapru; Christopher C Dvorak; Steve Miller; Charles Y Chiu; Joseph L DeRisi Journal: Am J Respir Crit Care Med Date: 2018-02-15 Impact factor: 21.405
Authors: Rosa Rodriguez-Fernandez; Lorena I Tapia; Chin-Fen Yang; Juan Pablo Torres; Susana Chavez-Bueno; Carla Garcia; Lisa M Jaramillo; Melissa Moore-Clingenpeel; Hasan S Jafri; Mark E Peeples; Pedro A Piedra; Octavio Ramilo; Asuncion Mejias Journal: J Infect Dis Date: 2017-12-27 Impact factor: 5.226
Authors: Wouter A A de Steenhuijsen Piters; Santtu Heinonen; Raiza Hasrat; Eleonora Bunsow; Bennett Smith; Maria-Carmen Suarez-Arrabal; Damien Chaussabel; Daniel M Cohen; Elisabeth A M Sanders; Octavio Ramilo; Debby Bogaert; Asuncion Mejias Journal: Am J Respir Crit Care Med Date: 2016-11-01 Impact factor: 21.405
Authors: Jinsheng Yu; Derick R Peterson; Andrea M Baran; Soumyaroop Bhattacharya; Todd N Wylie; Ann R Falsey; Thomas J Mariani; Gregory A Storch Journal: J Infect Dis Date: 2019-04-01 Impact factor: 5.226